ABOUT US

Invivyd is a biopharmaceutical company on a mission to protect humans from serious viral diseases. The company is developing antibodies to transcend the limits of naturally occurring immunity to provide superior protection from viral diseases, beginning with COVID-19.

Weak and short-lived mucosal immunity is a hallmark of seasonal influenza, respiratory syncytial virus, as well as SARS CoV-2, the virus that has driven the global COVID-19 pandemic.

SARS-CoV-2 continues to inflict an unacceptable burden on humankind. The antibody immune response to vaccines has helped keep us alive but leaves us at continued risk. Nonetheless, SARS-COV-2 remains a leading cause of U.S. death in 2022. To be safe and well, we require higher quality, more durable antibodies than our immune systems can produce in response to vaccination or infection.

We must close the gap between the antibodies we can make ourselves and the antibodies we need for safety, wellness and normal human functioning.

Invivyd is committed to addressing this unmet need by developing engineered antibodies superior to naturally occurring human antibodies.

Our discovery technology and platform is designed to match and overcome the challenges of viral evolution.

Our platform approach has yielded a pipeline of next generation engineered antibodies designed to provide robust and broad neutralization across past and current SARS-CoV-2 variants of concern, including wildtype, Beta, Delta, and Omicron BA1, BA2, BA5, and BA2.75.

Beyond COVID-19, we are leveraging our robust antibody discovery and development capabilities to develop therapeutic or preventative options for other respiratory viral infections, such as seasonal influenza.

Management Team

David Hering, M.B.A

David Hering, M.B.A

Chief Executive Officer & Director

Jill Andersen, J.D.

Jill Andersen, J.D.

Chief Legal Officer & Corporate Secretary

Fred Driscoll

Fred Driscoll

Interim Chief Financial Officer

Kyra Rosow Faircloth

Kyra Rosow Faircloth

Vice President of Government Affairs, Advocacy and Corporate Communications

Jeremy Gowler

Jeremy Gowler

Chief Operating & Commercial Officer

Julie Green, M.B.A.

Julie Green, M.B.A.

Senior Vice President, Human Resources

Pete Schmidt, M.D., M.S.

Pete Schmidt, M.D., M.S.

Chief Medical Officer

Heidi Spurling

Heidi Spurling

Vice President of Strategy and Operations & Chief of Staff

Board of Directors

Tamsin Berry

Partner, Population Health Partners

Marc Elia

Founder and Chief Investment Officer, M28 Capital Management L.P., Chairperson of the Board

David Hering, M.B.A

Chief Executive Officer & Director

Tom Heyman

Former President, Johnson & Johnson Development Corporation (JJDC)

Terry McGuire

Partner, Polaris Partners

Clive A. Meanwell, M.D.

Executive Chair and Co-founder, Population Health Partners

Christine Lindenboom

Senior Vice President, Alnylam Pharmaceuticals, Inc.

Michael Wyzga

President, MSW Consulting, Inc.